" class="no-js "lang="en-US"> Mirati Therapeutics Archives - Medtech Alert
Wednesday, May 31, 2023

Sort by:

Date

Top Post

SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbial Gene Therapy

SNIPR Biome, the company pioneering CRISPR microbial gene therapy, has announced positive interim clinical results […]

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Laurie Stelzer as […]

Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to […]

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement […]

  1. Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer’s Dementia Validation Trial Read more
  2. Cartography Biosciences Expands Scientific Advisory Board with Leading Antibody and Bi-specific Experts Read more
  3. Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection Applications for Translational Research and Precision Therapeutics Read more
  4. Ostentus Therapeutics and City of Hope to Continue Studies of Novel OST Natural Products for Treatment of Leukemia and Other Cancers Read more
  5. Cellular Origins launches Constellation, its Configurable Robotic Platform to Enable Scalable Manufacture of Advanced Therapies Read more